News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Heart Risk Seen With GlaxoSmithKline (GSK)'s Zofran?


6/29/2012 12:37:55 PM

GlaxoSmithKline has made changes in the dosage label for its anti-nausea drug Zofran, U.S. health regulators said.

The U.S. Food and Drug Administration on Friday said interim data from a clinical study showed a 32 mg single dose of Zofran could cause a potential risk of abnormal hearth rhythm.

Read at Reuters
Read at News Release

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES